Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

748 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Current treatment strategies in Hodgkin lymphomas.
Copeland A, Younes A. Copeland A, et al. Among authors: younes a. Curr Opin Oncol. 2012 Sep;24(5):466-74. doi: 10.1097/CCO.0b013e32835689a3. Curr Opin Oncol. 2012. PMID: 22871744 Review.
Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma.
Oki Y, Buglio D, Fanale M, Fayad L, Copeland A, Romaguera J, Kwak LW, Pro B, de Castro Faria S, Neelapu S, Fowler N, Hagemeister F, Zhang J, Zhou S, Feng L, Younes A. Oki Y, et al. Among authors: younes a. Clin Cancer Res. 2013 Dec 15;19(24):6882-90. doi: 10.1158/1078-0432.CCR-13-1906. Epub 2013 Oct 4. Clin Cancer Res. 2013. PMID: 24097867 Free PMC article. Clinical Trial.
Histone deacetylase inhibitors in lymphoma.
Copeland A, Buglio D, Younes A. Copeland A, et al. Among authors: younes a. Curr Opin Oncol. 2010 Sep;22(5):431-6. doi: 10.1097/CCO.0b013e32833d5954. Curr Opin Oncol. 2010. PMID: 20683267 Review.
Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma.
Younes A, Kim S, Romaguera J, Copeland A, Farial Sde C, Kwak LW, Fayad L, Hagemeister F, Fanale M, Neelapu S, Lambert JM, Morariu-Zamfir R, Payrard S, Gordon LI. Younes A, et al. J Clin Oncol. 2012 Aug 1;30(22):2776-82. doi: 10.1200/JCO.2011.39.4403. Epub 2012 Jul 2. J Clin Oncol. 2012. PMID: 22753910 Free PMC article. Clinical Trial.
Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes.
Younes A, Romaguera J, Fanale M, McLaughlin P, Hagemeister F, Copeland A, Neelapu S, Kwak L, Shah J, de Castro Faria S, Hart S, Wood J, Jayaraman R, Ethirajulu K, Zhu J. Younes A, et al. J Clin Oncol. 2012 Nov 20;30(33):4161-7. doi: 10.1200/JCO.2012.42.5223. Epub 2012 Sep 10. J Clin Oncol. 2012. PMID: 22965964 Free PMC article. Clinical Trial.
748 results